End of Enrollment for Pediatric Phase III Trial
GCT has successfully concluded enrollment for the Phase III pediatric study of rare neurological disease in Russia. Reaching the exact recruitment number, as predicted and in under 1.5 months marks an important milestone for our company and the Sponsor – US Pharma and GCT long term partner. Together, we were able to meet the projected deliverables despite the demanding timelines, sensitive patient group and limited number of sites that treat this devastating condition in Russia. The treatment phase of the study is now well underway according to the protocol schedule.
Updated: January 22, 2020
Permanent link: https://2022.gctrials.com/news/end-of-enrollment-for-pediatric-phase-iii-trial/